ArticleExperimental and therapeutic medicine2013
Inhibitory role of S-nitrosoglutathione in the aggregation of frozen platelets, and its effect on the expression of membrane glycoproteins.
Article in Experimental and therapeutic medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Effect of Nitric Oxide Donor on Metabolism of Apheresis Platelets.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2018Article
- Toxic effects of dimethyl sulfoxide on red blood cells, platelets, and vascular endothelial cellsFEBS open bio · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to explore the effects of S-nitrosoglutathione (GSNO) on the aggregation of frozen platelets, the platelet nitric oxide (NO) content and the expression of membrane glycoproteins. The level of frozen platelet aggregation was measured using a platelet aggregation analyzer, while the content of NO was measured by the nitrate reductase method and the expression of frozen platelet membrane glycoproteins was determined by flow cytometry. The level of frozen platelet aggregation was reduced from 35.47±2.93 to 24.43±3.07% following treatment with GSNO. The mean NO concentration in the 32 samples of frozen platelets treated with GSNO was 45.64±6.31 μmol/l, which was significantly higher compared with the concentration in the fresh liquid platelet group. There were no significant differences in the levels of PAC-1 in the fresh liquid platelet, frozen platelet and GSNO-treated frozen platelet groups; by contrast, significant differences were observed in the CD42b and CD62P levels. The platelet membrane glycoprotein expression levels in the frozen platelet and the GSNO-treated frozen platelet groups were not significantly different. The results of the study indicate that GSNO has potential as a cryoprotectant, due to its ability to increase the NO concentration in frozen platelets, inhibit platelet aggregation and maintain platelet function. It is likely that the molecular arrangement and structure of the frozen platelets were altered following GSNO treatment, or that the frozen platelets were affected by alternative mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.